These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8418041)

  • 1. Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.
    Verheul AF; Van Gaans JA; Wiertz EJ; Snippe H; Verhoef J; Poolman JT
    Infect Immun; 1993 Jan; 61(1):187-96. PubMed ID: 8418041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates.
    Verheul AF; Boons GJ; Van der Marel GA; Van Boom JH; Jennings HJ; Snippe H; Verhoef J; Hoogerhout P; Poolman JT
    Infect Immun; 1991 Oct; 59(10):3566-73. PubMed ID: 1910006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates.
    Verheul AF; Braat AK; Leenhouts JM; Hoogerhout P; Poolman JT; Snippe H; Verhoef J
    Infect Immun; 1991 Mar; 59(3):843-51. PubMed ID: 1900063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response.
    Steeghs L; Kuipers B; Hamstra HJ; Kersten G; van Alphen L; van der Ley P
    Infect Immun; 1999 Oct; 67(10):4988-93. PubMed ID: 10496868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis.
    Hoogerhout P; Donders EM; van Gaans-van den Brink JA; Kuipers B; Brugghe HF; van Unen LM; Timmermans HA; ten Hove GJ; de Jong AP; Peeters CC
    Infect Immun; 1995 Sep; 63(9):3473-8. PubMed ID: 7543883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of the adjuvant Quil A on the epitope specificity of meningococcal lipopolysaccharide anti-carbohydrate antibodies.
    Verheul AF; Poolman JT; Snippe H; Verhoef J
    Mol Immunol; 1991 Nov; 28(11):1193-200. PubMed ID: 1720502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens.
    Nagaputra JC; Rollier CS; Sadarangani M; Hoe JC; Mehta OH; Norheim G; Saleem M; Chan H; Derrick JP; Feavers I; Pollard AJ; Moxon ER
    Clin Vaccine Immunol; 2014 Feb; 21(2):234-42. PubMed ID: 24351756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.
    van der Voort ER; van der Ley P; van der Biezen J; George S; Tunnela O; van Dijken H; Kuipers B; Poolman J
    Infect Immun; 1996 Jul; 64(7):2745-51. PubMed ID: 8698504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates.
    Gu XX; Tsai CM
    Infect Immun; 1993 May; 61(5):1873-80. PubMed ID: 8478076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of meningococcal outer membrane protein vaccines solubilized with detergent or C polysaccharide.
    Poolman JT; Timmermans HA; Hopman CT; Teerlink T; Van Vught PA; Witvliet MH; Beuvery EC
    Antonie Van Leeuwenhoek; 1987; 53(6):413-9. PubMed ID: 3130780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination.
    Sjursen H; Wedege E; Rosenqvist E; Naess A; Halstensen A; Matre R; Solberg CO
    APMIS; 1990 Dec; 98(12):1061-9. PubMed ID: 2126441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-dependent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis.
    Estabrook MM; Jarvis GA; McLeod Griffiss J
    Infect Immun; 2007 Feb; 75(2):1025-33. PubMed ID: 17101655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of in vitro folded outer membrane protein PorA of Neisseria meningitidis.
    Jansen C; Kuipers B; van der Biezen J; de Cock H; van der Ley P; Tommassen J
    FEMS Immunol Med Microbiol; 2000 Mar; 27(3):227-33. PubMed ID: 10683467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis.
    Rosenqvist E; Musacchio A; Aase A; Høiby EA; Namork E; Kolberg J; Wedege E; Delvig A; Dalseg R; Michaelsen TE; Tommassen J
    Infect Immun; 1999 Mar; 67(3):1267-76. PubMed ID: 10024570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection.
    Rosenqvist E; Harthug S; Frøholm LO; Høiby EA; Bøvre K; Zollinger WD
    J Clin Microbiol; 1988 Aug; 26(8):1543-8. PubMed ID: 3139705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution.
    van de Wijgert JH; Verheul AF; Snippe H; Check IJ; Hunter RL
    Infect Immun; 1991 Aug; 59(8):2750-7. PubMed ID: 1855991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.
    Fransen F; Boog CJ; van Putten JP; van der Ley P
    Infect Immun; 2007 Dec; 75(12):5939-46. PubMed ID: 17908810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and immunogenicity of serogroup B meningococcal OS-OMPC conjugates.
    Sun YY; Hu XJ
    Biomed Environ Sci; 1999 Dec; 12(4):296-303. PubMed ID: 10840586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects.
    Cross AS; Opal SM; Palardy JE; Drabick JJ; Warren HS; Huber C; Cook P; Bhattacharjee AK
    Vaccine; 2003 Nov; 21(31):4576-87. PubMed ID: 14575770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A linear B-cell epitope on the class 3 outer-membrane protein of Neisseria meningitidis recognized after vaccination with the Norwegian group B outer-membrane vesicle vaccine.
    Delvig AA; Wedege E; Caugant DA; Dalseg R; Kolberg J; Achtman M; Rosenqvist E
    Microbiology (Reading); 1995 Jul; 141 ( Pt 7)():1593-600. PubMed ID: 7551027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.